Public Services Division
Databases and Other Resources
CenterWatch is a source of clinical trials information for both clinical research professionals and patients. Boston: CenterWatch; 1995- .
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Bethesda(MD): National Library of Medicine; 2000- .
Elsevier Intelligence Business Publications includes search of articles in biopharma related newsletters like the Tan Sheet, Gold Sheet, Silver Sheet, Pharmaceuticals Approval Monthly, and In Vivo. Subscription required for full text access or check your libraries for access to print or electronic newsletters. Philadelphia: Elsevier Business Intelligence; 2013- .
Health Business Elite contains nearly 600 journals dealing with the health care industry, non-clinical aspects of health care, marketing and health care administration. Many have full text links. Ipswich (MA): EBSCOhost; 2009- .
Pharmaprojects contains detailed profiles of over 50,000 drugs, covering all drugs for all diseases, from the preclinical to commercialization stage. London: Citeline/Informa Health Business; Subscription required.
Pipeline: Business intelligence source monitoring global pharma and biotech R & D, London: Citeline/Informa Healthcare Business; 2007- . Subscription required.
Biologics Regulated Products regulated by FDA Center for Biologics Evaluation and Research (CBER) still regulates allergenics, blood and blood products, cellular and gene therapy, tissue and tissue products, vaccines, and xenotransplantation.
Brody T. Clinical Trials: study design, endpoints, and biomarkers, drug safety, and FDA and ICH guidelines. New York: Academic Press; 2012.
Gad SC. Development of Therapeutic Agents Handbook. New York: Wiley; 2012.
Li JJ, Corey EJ, editors. Drug Discovery: practices, processes, and perspectives. Hoboken (NJ): John Wiley & Sons; 2013.
Medicines in Development, Washington (DC): Pharmaceutical Research and Manufacturers of America; 2013- .
New Drug Applications (NDA) has been the basis of the regulation and control of new drugs in the United States by the Food and Drug Administration since 1938. Every new drug has been the subject of an approved NDA before U.S. commercialization. Other FDA CDER Evaluation applications include:
- Investigational New Drug (IND) Applications. Current federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines.
- Therapeutic Biologic Applications (TBA) which regulates monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, therapeutic proteins and recombinant versions of these products, and other non-vaccine therapeutic immunotherapies.
- Abbreviated New Drug Applications (ANDA) for generic drugs.
New Medicines Database of the European Medicines Agency. London: European Medicines Agency; 1995- .
Plunkett JW. Plunkett’s Biotech & Genetics Industry Almanac. Houston (TX): Plunkett Research; 2000- . Includes listing of Biotech 350 International Companies), as well as, industry information and selective statistics.
Plunkett JW. Health Care Industry Almanac. Houston (TX): Plunkett Research; 1995- . Includes profiles of the Health Care 500 companies, as well as, industry information and selective statistics.
Spilker B. Guide to Drug Development: a comprehensive review and assessment. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.